查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610264

胸膜炎治疗市场：按诊断、治疗、给药方法和最终用户分类 - 全球预测 2025-2030

Pleurodynia Treatment Market by Diagnosis (Blood Test, Culture Test, X-ray), Treatment (Analgesics, Immunoglobulin), Mode Of Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，胸膜炎治疗市值为1.3843亿美元，预计到2024年将达到1.454亿美元，复合年增长率为5.66%，到2030年将达到2.0354亿美元。

胸膜炎，俗称博恩霍姆病，是一种急性病毒感染疾病，会导致下胸部和上腹部严重肌肉疼痛。它通常由柯萨奇 B 病毒引起，治疗重点是症状管理而不是彻底治疗。胸膜炎治疗的需要源自于急性且常常使人衰弱的症状，这些症状严重限制了患者的运动能力和生活品质。治疗主要是安宁疗护，使用止痛药和发炎药物来缓解疼痛和减少发炎。最终用途包括提供初级和支持性护理的医院、诊所和门诊机构。

主要市场统计
基准年[2023] 1.3843亿美元
预测年份 [2024] 1.454 亿美元
预测年份 [2030] 20354万美元
复合年增长率（%） 5.66%

市场成长受到病毒感染疾病爆发和对有效疼痛管理解决方案日益增长的需求的影响。关键的成长要素包括抗病毒治疗的进步、对病毒感染影响的认识以及有助于更好管理方法的快速诊断方法的发展。机会包括开发更有效的抗病毒药物、针对病毒根源的治疗方法以及快速止痛解决方案的创新。该公司的主要机会包括多元化发展非处方疼痛管理解决方案，以及与医疗提供者合作提供全面的护理服务。

然而，对胸膜炎流行病学的了解有限以及现有治疗方法的潜在副作用等挑战限制了成长。由于具体治疗方法有限且该疾病依赖对症治疗，因此有人指出需要研究新的治疗方法。新药的监管障碍和严格的核准程序也可能抑制市场势头。

预计创新的领域包括开发标靶抗病毒疗法和探索使用生物技术来增强疼痛管理解决方案并使治疗更安全、更有效。由于这个市场以患者为中心，往往强调症状缓解，因此快速识别胸膜透析的增强诊断工具有可能显着改善患者预后并推动市场扩张。由于该市场的高度专业化性质，製药公司和医疗保健组织之间建立牢固的伙伴关係对于促进永续成长和解决治疗差异至关重要。

市场动态：揭示快速发展的胸膜炎治疗市场的关键市场洞察

供需的动态交互作用正在改变胸膜炎治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 病毒感染疾病和胸膜炎盛行率增加
    • 活性化新药引进的研发活动
  • 市场限制因素
    • 研发成本上升
  • 市场机会
    • 医疗成果的技术进步与现代化
  • 市场问题
    • 严格的监管指引

波特的五力：驾驭胸膜炎治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胸膜炎治疗市场的外部影响

外部宏观环境因素在塑造胸膜炎治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解胸膜炎治疗市场的竞争格局

对胸膜炎治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：胸膜炎治疗市场供应商的绩效评估

FPNV定位矩阵是评估胸膜炎治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製胸膜炎治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，胸膜炎治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 病毒感染疾病和胸膜炎盛行率增加
      • 活性化新药引进的研发活动
    • 抑制因素
      • 研发活动成本上升
    • 机会
      • 医疗成果的技术进步与现代化
    • 任务
      • 严格的监管指引
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章胸膜炎治疗市场：依诊断

  • 介绍
  • 验血
  • 文化测试
  • X射线

第七章胸膜炎治疗市场：依治疗分类

  • 介绍
  • 止痛药
  • 免疫球蛋白

第八章胸膜炎治疗市场：依给药方式分类

  • 介绍
  • 注射
  • 口服

第九章胸膜炎治疗市场：依最终使用者分类

  • 介绍
  • 医院
  • 药局

第10章美洲胸膜炎治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太胸膜炎治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的胸膜炎治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck and Co. Inc.
  • Novartis AG
  • Opsonin Pharma Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
Product Code: MRR-742BD51839D5

The Pleurodynia Treatment Market was valued at USD 138.43 million in 2023, expected to reach USD 145.40 million in 2024, and is projected to grow at a CAGR of 5.66%, to USD 203.54 million by 2030.

Pleurodynia, commonly known as Bornholm disease, is an acute viral infection leading to severe muscle pain in the lower chest and upper abdomen. Often caused by Coxsackie B viruses, its treatment primarily focuses on symptom management rather than a definitive cure. The necessity of pleurodynia treatment arises from its acute, often debilitating symptoms, which can severely restrict patient mobility and quality of life. Applications of treatment are mainly palliative, involving analgesics and anti-inflammatory medications, to alleviate pain and reduce inflammation. The end-use scope includes hospitals, clinics, and outpatient settings where primary and supportive care are administered.

KEY MARKET STATISTICS
Base Year [2023] USD 138.43 million
Estimated Year [2024] USD 145.40 million
Forecast Year [2030] USD 203.54 million
CAGR (%) 5.66%

Market growth is influenced by the prevalence of viral infections and the increasing demand for effective pain management solutions. Key growth factors include advancements in antiviral therapies, awareness of viral infection ramifications, and the development of rapid diagnostics contributing to better management practices. Opportunities arise in creating more effective antiviral drugs or therapies targeting the root viral causes, along with innovations in fast-acting pain relief solutions. For businesses, diversification into over-the-counter pain management solutions and partnerships with healthcare providers for comprehensive care packages present key opportunities.

However, challenges such as limited understanding of the epidemiology of pleurodynia, coupled with potential side effects of existing treatments, pose growth constraints. Limited specific drug treatments and reliance on symptomatic relief indicate the need for novel therapeutic research. Regulatory hurdles and stringent approval processes for new drug entities may also dampen market momentum.

Promising areas for innovation include developing targeted antiviral therapies and exploring the use of biotechnology to enhance pain management solutions, making treatments safer and more efficient. As the market is patient-centric with an inclination towards symptomatic relief, enhanced diagnostic tools to rapidly identify pleurodynia can significantly elevate patient outcomes and drive market expansion. The nature of this market is highly specialized, emphasizing the creation of robust partnerships between pharmaceutical entities and healthcare institutions to drive sustained growth and address treatment gaps.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pleurodynia Treatment Market

The Pleurodynia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of viral infections and increasing prevalence of pleurodynia disease
    • Rising R&D activities for introducing new medications
  • Market Restraints
    • Rise in the cost of research and development activities
  • Market Opportunities
    • Technological advancements and modernization in the healthcare outcomes
  • Market Challenges
    • Stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Pleurodynia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pleurodynia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pleurodynia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pleurodynia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pleurodynia Treatment Market

A detailed market share analysis in the Pleurodynia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pleurodynia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pleurodynia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pleurodynia Treatment Market

A strategic analysis of the Pleurodynia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pleurodynia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Limited, Cipla Limited, Dr. Reddy's Laboratories, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs, Johnson & Johnson Services, Inc., Lupin Limited, Merck and Co. Inc., Novartis AG, Opsonin Pharma Ltd., Pfizer Inc., Reckitt Benckiser Group PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Pleurodynia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnosis, market is studied across Blood Test, Culture Test, and X-ray.
  • Based on Treatment, market is studied across Analgesics and Immunoglobulin.
  • Based on Mode Of Administration, market is studied across Injections and Oral.
  • Based on End-User, market is studied across Hospitals and Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of viral infections and increasing prevalence of pleurodynia disease
      • 5.1.1.2. Rising R&D activities for introducing new medications
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in the cost of research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements and modernization in the healthcare outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pleurodynia Treatment Market, by Diagnosis

  • 6.1. Introduction
  • 6.2. Blood Test
  • 6.3. Culture Test
  • 6.4. X-ray

7. Pleurodynia Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Analgesics
  • 7.3. Immunoglobulin

8. Pleurodynia Treatment Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Injections
  • 8.3. Oral

9. Pleurodynia Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Pharmacy

10. Americas Pleurodynia Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pleurodynia Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pleurodynia Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Limited
  • 3. Cipla Limited
  • 4. Dr. Reddy's Laboratories
  • 5. GlaxoSmithKline PLC
  • 6. Glenmark Pharmaceuticals Limited
  • 7. Hetero Drugs
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lupin Limited
  • 10. Merck and Co. Inc.
  • 11. Novartis AG
  • 12. Opsonin Pharma Ltd.
  • 13. Pfizer Inc.
  • 14. Reckitt Benckiser Group PLC
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. PLEURODYNIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PLEURODYNIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PLEURODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PLEURODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PLEURODYNIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PLEURODYNIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. PLEURODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. PLEURODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023